Molecular mechanisms in psoriasis: historical perspective and current pathogenesis

References

• Tsoi LC, Spain SL, Knight J et al.; Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44(12), 1341–1348 (2012).
   PubMed Web of Science ®Google Scholar
• Farber EM, McClintock RP Jr. A current review of psoriasis. Calif. Med. 108(6), 440–457 (1968).
   PubMedGoogle Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495–497 (1975).
   PubMed Web of Science ®Google Scholar
• Yanagi Y, Yoshikai Y, Leggett K, Clark SP, Aleksander I, Mak TW. A human T-cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 308(5955), 145–149 (1984).
   PubMed Web of Science ®Google Scholar
• Hedrick SM, Nielsen EA, Kavaler J, Cohen DI, Davis MM. Sequence relationships between putative T-cell receptor polypeptides and immunoglobulins. Nature 308(5955), 153–158 (1984).
   PubMed Web of Science ®Google Scholar
• Smith KA, Lachman LB, Oppenheim JJ, Favata MF. The functional relationship of the interleukins. J. Exp. Med. 151(6), 1551–1556 (1980).
   PubMed Web of Science ®Google Scholar
• Sauder DN, Carter CS, Katz SI, Oppenheim JJ. Epidermal cell production of thymocyte activating factor (ETAF). J. Invest. Dermatol. 79(1), 34–39 (1982).
   PubMed Web of Science ®Google Scholar
• Luger TA, Stadler BM, Luger BM et al. Murine epidermal cell-derived thymocyte-activating factor resembles murine interleukin 1. J. Immunol. 128(5), 2147–2152 (1982).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256(22), 3110–3116 (1986).
   PubMed Web of Science ®Google Scholar
• Kono T, Kondo S, Venner TJ, Sauder DN, McKenzie RC. Inhibition of cytokine gene expression in mouse skin by subcutaneous injection of cyclosporine. Skin Pharmacol. 8(3), 149–155 (1995).
   PubMedGoogle Scholar
• Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1(5), 442–447 (1995).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol. 49(Suppl. 2), S87–S97 (2003).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK et al.; Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349(21), 2004–2013 (2003).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al.; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 366(9494), 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. 42(5 Pt 1), 829–830 (2000).
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136(7), 2348–2357 (1986).
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366(13), 1190–1199 (2012).
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366(13), 1181–1189 (2012).
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199(1), 125–130 (2004).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C et al.; CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356(6), 580–592 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis. Model. Mech. 5(4), 423–433 (2012).
   PubMed Web of Science ®Google Scholar
• Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu. Rev. Pathol. 7, 385–422 (2012).
   PubMed Web of Science ®Google Scholar
• Cai Y, Fleming C, Yan J. New insights of T-cells in the pathogenesis of psoriasis. Cell. Mol. Immunol. 9(4), 302–309 (2012).
   PubMed Web of Science ®Google Scholar
• Stetsko D, Sauder DN. IL-12 and IL-23 in health and disease. Expert Rev. Clin. Immunol. 4(3), 301–303 (2008).
   PubMed Web of Science ®Google Scholar